When testing for the possibility of certain types of cancer, doctors often do surgery to retrieve biopsies for genetic analysis. But when a patient has already had cancer, and is testing for a possibility of recurrence, Helmy Eltoukhy, the co-founder of medical tech startup Guardant Health, believes that a blood test could replace a biopsy and avoid surgery.
A startup has developed new technology that it claims can open a new front in the war on cancer. Guardant Health has developed a non-invasive screening tool that relies on a blood sample rather than tissue. The test, dubbed the “Guardant 360,” is designed to help patients avoid risky and expensive biopsies. Biopsies can cost up to $10,000 for people not covered by insurance. By contrast, Guardant expects its test to be available for a few hundred dollars. The Redwood City, Calif.-based company announced this week that it will begin selling its genetic screening tool to some 100,000 patients in a handful of cancer clinics. Guardant also disclosed that it has raised $10 million in capital fromSequoia Capital, a venture firm that is increasingly investing in the personalized medicine trend. Sequoia’s health investor, Warren Hogarth, has joined the company’s board.
NOTE: TECHi Two-Takes are the stories we have chosen from the web along with a little bit of our opinion in a paragraph. Please check the original story in the Source Button below.
TECHi weighs both sides before reaching a conclusion.
TECHi’s editorial take above outlines the reasoning that supports this position.
A profile has been popping on Tinder this week for users in Austin. Many of the attendees of the SXSW…
The Department of Justice and the NSA are being sued by the Wikimedia Foundation with the goal of ending "this mass…
Transparency reports have pretty much become a must-have for Internet companies, with the big companies like Facebook and Google releasing massive…
We've already established that Valve's highly-anticipated Steam Machines will finally be hitting the market this November, but what will the…
